Lung cancer is the world's most common cancer and kills more people than any other cancer. In 2008, approximately 1.52 million new cases of lung cancer were diagnosed worldwide, with 1.31 million people dying from the disease.(14) In the United States, an estimated 161,840 deaths, accounting for 29 percent of all cancer deaths, occurred in 2008, according to the American Cancer Society (ACS).
The human immune system is notably adept at evading tumor cells, which construct physical barriers, adopt masks, and restrain the immune system with molecular ploys.
A new Cleveland Clinic study has uncovered vital information about the cellular interaction of tumor cells and normal tissue, leading to a better understanding of how therapeutic resistance evolves.
Lung cancer affects approximately 48,500 persons in the United Kingdom every year. New treatments are urgently needed because only around 20% of patients live 5 years after diagnosis, and it is the leading cause of cancer death.
The University of Texas MD Anderson Cancer Center scientists have created an ultrasound-guided cancer immunotherapy approach that promotes systemic antitumor immunity and increases immune checkpoint blockade therapeutic potential. Nature Nanotechnology published the results of the pioneering study.
In cancer management, biomarkers are commonly used to guide treatment decisions and evaluate patient outcomes.
According to research published in eLife, scientists have discovered a mechanism that explains how small air pollution particles may cause lung cancer.
Cancer researchers at the Case Western Reserve University School of Medicine say they have successfully suppressed the growth of some solid tumors in research models by manipulating immune cells known as a macrophages.
Doctors commonly use tyrosine kinase inhibitors, particularly epidermal growth factor receptor inhibitors, to cure patients with non-small cell lung cancer, a common and typically deadly kind of cancer that accounts for 80% to 85% of lung cancers.
Bacteria promote cancer metastasis by bolstering the strength of host cells against mechanical stress in the bloodstream, promoting cell survival during tumor progression, researchers report April 7th in the journal Cell.
While cancer therapies that target specific genes or disease pathways might prolong life span, they can also result in highly resistant tumors when tiny reservoirs of cancer cells survive therapy, develop, and spread.
Scientists develop a new fluorescent label that provides a sharper image of how DNA architecture is disturbed in cancer cells.
Researchers at the University of Michigan Rogel Cancer Center found that a cytokine, a category of protein that acts as messengers in the body, and a fatty acid can work together to trigger a type of cell death previously defined by studies with synthetic molecules.
Joint study will assess clinical value of comprehensive genomic profiling (CGP) on cancer therapy options in patients with advanced disease
Lung cancer is the second leading cancer in the United States and the No. 1 cause of cancer-associated deaths.
Cancerous tumors are made up of rapidly growing, abnormally shaped, cells that can infiltrate and destroy healthy tissues, travel to other parts of the body, and form additional tumors.
An olfactory receptor gene that aids in the sense of smell may also play a role in the metastasis of breast cancer to the brain, bones and lung, researchers from Massachusetts General Hospital have found.
In the last 10 years, immunotherapy has been used to save the lives of several cancer patients with lung cancer.
Some studies have shown that nicotine, an addictive substance in electronic cigarettes, increases the risk of cardiovascular and respiratory disorders.
Immunotherapies are exhibiting better clinical benefit in the treatment of numerous cancers, particularly when used along with chemotherapy.
Significant changes in lipid metabolism are known to occur in cells associated with non-small-cell lung carcinoma – the most common form of lung cancer.